ID: ALA557779

Max Phase: Preclinical

Molecular Formula: C24H27ClN4O5S

Molecular Weight: 482.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1ccc(S(=O)(=O)Nc2ccc(C)c(CC(=O)NCc3ccc(C(=N)N)cc3)c2O)cc1.Cl

Standard InChI:  InChI=1S/C24H26N4O5S.ClH/c1-15-3-12-21(28-34(31,32)19-10-8-18(33-2)9-11-19)23(30)20(15)13-22(29)27-14-16-4-6-17(7-5-16)24(25)26;/h3-12,28,30H,13-14H2,1-2H3,(H3,25,26)(H,27,29);1H

Standard InChI Key:  RTRAZYAPJORJLJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 482.56

Molecular Weight (Monoisotopic): 482.1624

AlogP: 2.65

#Rotatable Bonds: 9

Polar Surface Area: 154.60

Molecular Species: BASE

HBA: 6

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 7.37

CX Basic pKa: 11.41

CX LogP: 2.59

CX LogD: 2.32

Aromatic Rings: 3

Heavy Atoms: 34

QED Weighted: 0.18

Np Likeness Score: -1.00

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature